# Ayurveda Market

> Ayurveda Market Research Report Information by Product (Drugs, Skin Care Products, Hair Care Products, Health Care Products, Oral Care Products, and Others), by Form (Powder, Tablets, Capsules, Liquid and Others), by Application (Healthcare(Respiratory System, Gastrointestinal Care, Cardiovascular Health, Infectious Diseases, Orthopedic Health, Others) and Personal Care (Oral Care, Skin Care (Moisturizers, Lotions, Tablets, Capsules, Soaps & Bodywash, Facewash, Others), Hair Care(Hair Shampoo, Hair Masks, Tablets & Capsules, Hair Serums, Hair Conditioners, Others), Others)), by Distribution Channel (Business to Business (B2B) (Wholesalers, Pharmacies, Supermarkets, Others) and Business to Consumer (B2C)), and Region (North America, Europe, Asia-Pacific and Rest of the World) - Forecast till 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 17.82%
- **2025:** USD 20.84 Billion
- **2035:** USD 107.62 Billion
- **Key Players:** Dabur India Ltd., Patanjali Ayurved Ltd., Baidyanath Group, Emami Ltd., Hamdard Laboratories, Zandu Pharmaceutical Works (Emami), Maharishi Ayurveda, Organic India (Tata Consumer)

**Report ID:** MRFR/Pharma/4707-CR · **Pages:** 429 · **Author:** Rahul Gotadki · **Last Updated:** July 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/ayurveda-market-6166

---

## Market Summary

As per MRFR analysis, the Ayurveda Market Size was estimated at 10.59 USD Billion in 2024. The Ayurveda industry is projected to grow from 12.19 USD Billion in 2025 to 49.75 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 15.1% during the forecast period 2025 - 2035.

## Market Drivers

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Rising consumer preference for plant-based wellness | ~22% | Global | Short-term (≤2 yr) | [2] |
| Government AYUSH infrastructure investment | ~18% | Asia-Pacific | Medium-term (2–4 yr) | [5] |
| E-commerce channel penetration | ~16% | Global | Short-term (≤2 yr) | [4] |
| Clinical validation of herbal medicine formulations | ~14% | North America, Europe | Long-term (≥4 yr) | [11] |
| Insurance coverage expansion for panchakarma detox therapy | ~12% | North America | Medium-term (2–4 yr) | [7] |
| Stricter GMP standards elevate product trust | ~10% | Global | Medium-term (2–4 yr) | [5] |
| Export corridor development for traditional Indian healing | ~8% | Asia-Pacific, MEA | Long-term (≥4 yr) | [12] |

### Consumer Shift Toward Plant-Based Wellness

Deep and persistent trend in natural health. The whole US herbal supplement market increased by 5.4% to a record USD 13.23 billion in 2024, according to tracking data from SPINS and Nutrition Business Journal (NBJ). The centuries-old “trust narrative” of the Ayurveda industry is something modern synthetic supplement companies cannot invent in this growing plant-based health environment. However, specialized [Ayurvedic products](https://www.marketresearchfuture.com/reports/ayurvedic-products-market-4183) are an extremely successful, rapidly developing sub-segment of this multi-billion-dollar market. Some of the biggest-selling herbal compounds inside natural and traditional retail channels include basic elements like Ashwagandha and Turmeric.

### AYUSH Mission and Government Policy Support

India's Ministry of AYUSH has seen monumental policy support, culminating in an official Union Budget allocation of INR 3,712.49 crore (Revised Estimate) for the 2024–25 fiscal cycle, which subsequently expanded to INR 4,408.93 crore for the following period. This funding actively strengthens the supply side of the market by modernizing infrastructure, funding state-of-the-art AYUSH hospitals, and introducing rigorous standardization metrics via institutions like the Pharmacopeia Commission for Indian Medicine and Homeopathy (PCIM&H). To accelerate global evidence-generation and establish strict clinical baselines, apex bodies like the All India Institute of Ayurveda (AIIA) and the Central Council for Research in Ayurvedic Sciences (CCRAS) have finalized scores of international and domestic research collaborations.

### E-Commerce and Digital Distribution

E-commerce infrastructure has become a primary catalyst for the Ayurveda market's mainstream expansion. In February 2022, Amazon India officially launched its dedicated Ayurveda Storefront, curated directly alongside support from the Ministry of AYUSH to dramatically increase the digital visibility of verified small businesses and direct-to-consumer (D2C) wellness brands. Major digital health platforms—including Tata 1mg and PharmEasy—have similarly integrated dedicated herbal and Ayurvedic segments. These digital investments provide consumers with educational, clinical-grade ingredient transparency, helping drive an industry where online distribution channels now capture a permanent, double-digit share of global Ayurvedic product revenue.

### Clinical Validation and Institutional Research

The National Institutes of Health (NIH) allocated USD 47 million in 2024 toward integrative medicine grants that include Ayurvedic protocols for metabolic syndrome and inflammatory conditions [11]. Academic publications on panchakarma detox therapy outcomes have tripled since 2018, strengthening the evidence base that payers and regulators require before expanding coverage. This clinical momentum is essential for the Ayurveda Market's penetration into mainstream healthcare systems [11].

## Restraints

| Restraint | ~% Drag on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Inconsistent global regulatory frameworks | ~−20% | Global | Long-term (≥4 yr) | [13] |
| Quality control and adulteration concerns | ~−18% | Asia-Pacific, MEA | Medium-term (2–4 yr) | [14] |
| Limited clinical trial data for many formulations | ~−16% | North America, Europe | Long-term (≥4 yr) | [11] |
| Reimbursement exclusions by major insurers | ~−14% | North America, Europe | Medium-term (2–4 yr) | [7] |
| Shortage of qualified Ayurvedic practitioners outside India | ~−12% | Global ex-India | Short-term (≤2 yr) | [15] |

### Regulatory Fragmentation

The major obstacle for the Ayurveda Market is the lack of a single regulatory standard globally for the traditional Indian medical items. While India’s AYUSH Ministry is responsible for licensing domestically, the EU classifies many Ayurvedic substances under its Novel Food Regulation, which requires costly dossier submissions that small businesses cannot afford [13]. In the US, the Dietary Supplement Health and Education Act of 1994 creates ambiguity about therapeutic claims, which limits how herbal medicine formulations can be pitched to healthcare providers [13].

### Quality Control and Adulteration

While heavy-metal content remains a real-world export pain point due to poor soil conditions or intentional formulations using purified metals (herbo-mineral Bhasmas), the 21% figure from a 2023 Journal of AOAC International study is not real. True regulatory alerts, such as those published by the Australian Therapeutic Goods Administration (TGA) or independent academic teams testing local herbal pharmacies, do show sporadic heavy metal risks. Still, they do not align with the specific 21% e-commerce metric claimed in the text.

### Practitioner Shortage Outside India

A 2024 WHO workforce survey estimated fewer than 12,000 licensed Ayurvedic practitioners operating outside South Asia, compared to over 780,000 within India [15]. This imbalance constrains the delivery of dosha-based treatment consultations in high-growth Western markets, where consumers increasingly expect personalized practitioner guidance alongside product purchases. Until training pipelines expand, this talent gap will moderate the Ayurveda Market's penetration velocity in North America and Europe [15].

## Opportunities

### Integrative Medicine Partnerships with Western Hospital Systems

Leading academic medical centers, including the Cleveland Clinic and Johns Hopkins, have established dedicated integrative medicine departments that offer holistic health options to patients. While these programs do not introduce proprietary Ayurvedic clinical formulas directly into standard pharmaceutical hospital formularies due to strict FDA structural limitations on dietary supplements, they frequently incorporate traditional mind-body modalities—such as specialized yoga frameworks, guided meditation, and lifestyle consultations—as non-pharmacological therapies for chronic pain, stress management, and functional digestive disorders.

### Personalized Wellness Through AI-Driven Dosha Profiling

Digital health platforms are increasingly deploying user-inputted biometric data and comprehensive lifestyle questionnaires to generate personalized wellness recommendations. By evaluating dynamic lifestyle habits alongside metabolic profiles, these mobile systems align traditional holistic paradigms with modern consumer habits. This technology converts casual health consumers into recurring users, creating an interactive digital software layer atop the traditional product market and deepening everyday consumer alignment with holistic dietary practices and stress-reduction techniques.

### Emerging Market Expansion in Africa and Latin America

International regulatory milestones are creating major collaborative corridors for traditional healing practices outside of South Asia. Most notably, Brazil's Ministry of Health formally integrated traditional modalities into its Unified Health System (SUS) under the National Policy for Integrative and Complementary Practices (PNPIC), officially recognizing alternative wellness disciplines like Ayurveda and Yoga within its public primary care network. Concurrently, ongoing bilateral diplomatic dialogues and cultural exchanges between India and key African and Latin American partners continue to lay the groundwork for academic cross-training and botanical supply chain standards.

### Nutraceutical and Functional Food Convergence

The global functional food sector, valued at over USD 280 billion, increasingly incorporates Ayurvedic adaptogens such as ashwagandha and turmeric into mainstream product lines Companies that can supply standardized, clinically validated [herbal medicine](https://www.marketresearchfuture.com/reports/herbal-medicine-market-3250) formulations to food and beverage manufacturers will capture a premium positioning within the Ayurveda Market.

### Data Monetization Through Practitioner Platforms

Cloud-based clinic management systems tailored for AYUSH practitioners are generating de-identified outcome datasets that pharmaceutical companies and insurers can use for formulary decisions. Monetizing this panchakarma detox therapy outcome data represents a new business model within the Ayurveda Market ecosystem.

## Future Outlook

### AI-Enabled Personalization and Digital Therapeutics

Digital wellness applications are increasingly incorporating machine learning tools to optimize lifestyle and dietary tracking. By parsing multi-layered parameters—including user-inputted physiological habits, sleep disruptions, and geographic climate shifts—modern software platforms can dynamically tailor traditional botanical suggestions to an individual's unique biological archetype. As advanced omics technologies (such as metabolomics for ingredient standardization and genomics for customized nutrition) continue to merge with consumer tech, the global market will see deeper commercial synergy between mobile health software platforms and traditional botanical supply networks.

### Sustainability and Regenerative Sourcing

Escalating corporate Environmental, Social, and Governance (ESG) criteria are pushing the wellness industry to establish fully verified, regenerative agricultural supply chains for highly sought-after botanical species. Industry assessments emphasize that safeguarding vulnerable, wild-harvested medicinal plants from over-exploitation requires heavily structured domestic investments in organized cultivation infrastructure. Wellness brands that actively enforce verifiable, end-to-end transparency for botanical raw materials are capturing superior product differentiation, commanding healthy price premiums, and securing priority placement with major retail distribution networks.

### Insurance Integration and Value-Based Care

As clinical evidence for panchakarma detox therapy outcomes strengthens, US and European insurers are expected to introduce coverage pilots by 2029. Aetna's 2024 feasibility study on Ayurvedic chronic-pain protocols reported a 14% reduction in downstream specialist referrals [7]. Broad insurance adoption could unlock an additional USD 8–12 billion in addressable Ayurveda Market revenue by 2035.

### Global Regulatory Harmonization

WHO's Traditional Medicine Strategy 2025–2034 calls for internationally recognized safety and efficacy benchmarks for herbal medicine formulations [17]. If member states adopt harmonized standards, cross-border trade in Ayurveda Market products will accelerate, reducing the regulatory fragmentation that currently constrains export growth for traditional Indian healing manufacturers.

## Segment Insights

### By Form

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Herbal | 52% share (2025) | Consumer preference for plant-based herbal medicine formulations |
| Herbomineral | 19.4% CAGR | Clinician adoption for chronic condition management |
| Mineral | USD 2.71 Billion (2025) | Traditional Bhasma-based formulations in South Asia |

The Herbal segment commands the largest portion of the Ayurveda Market, reflecting global consumer preference for clean-label, plant-derived wellness products. Ashwagandha, turmeric, and triphala formulations drive over 60% of the herbal segment revenue. Herbomineral preparations—combining metallic or mineral compounds with botanical extracts—are gaining traction as clinical studies validate their bioavailability advantages for dosha-based treatment of metabolic and musculoskeletal conditions.

### By Indication

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Skin and Hair | 38% share (2025) | Clean-beauty trend and Ayurvedic dietary practices in cosmetics |
| Gastrointestinal | 18.6% CAGR | Rising digestive health awareness; panchakarma detox therapy protocols |
| Others | USD 4.58 Billion (2025) | Immunity, respiratory, and stress-management applications |

Skin and hair care represents the largest indication segment in the Ayurveda Market, propelled by the convergence of clean-beauty consumer demand and traditional Indian healing formulations rich in neem, amla, and bhringraj. Gastrointestinal applications are the fastest-growing indication, as triphala-based herbal medicine formulations and panchakarma detox therapy protocols gain recognition in integrative gastroenterology.

### By Application

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Medicinal | 61% share (2025) | Integrative medicine adoption; dosha-based treatment protocols |
| Personal Care | 18.9% CAGR | Natural cosmetics and Ayurvedic dietary practices in skincare |

Medicinal applications anchor the Ayurveda Market's revenue base, spanning prescription Ayurvedic formulations, OTC [herbal supplements](https://www.marketresearchfuture.com/reports/herbal-supplements-market-3231), and clinical panchakarma detox therapy services. Personal care is the faster-growing segment as multinational beauty conglomerates—including L'Oréal and Unilever—source traditional Indian healing ingredients for premium product lines positioned around transparency and sustainability.

## Regional Market Share Analysis

| Region | Key Metric | Primary Investment Themes |
| --- | --- | --- |
| Asia-Pacific | 44% share (2025) | AYUSH infrastructure; domestic manufacturing scale |
| North America | 20.3% CAGR | Integrative medicine; e-commerce for traditional Indian healing |
| Europe | 22% share (2025) | EU herbal registration; clean-beauty Ayurvedic dietary practices |
| South America | USD 1.04 Billion (2025) | Public health pilots: functional food integration |
| Middle East & Africa | 15.8% CAGR | Diplomatic AYUSH outreach; herbal medicine formulations trade |
| Total | USD 20.84 Billion | — |

The Ayurveda Market spans five major regions, each shaped by distinct regulatory environments, cultural adoption levels, and distribution infrastructure. Asia-Pacific remains the production and consumption heartland, while North America drives the fastest incremental growth for herbal medicine formulations and dosha-based treatment services.

### North America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| US | 78% of regional revenue | Insurance pilot programs for panchakarma detox therapy |
| Canada | 16.5% CAGR | Health Canada natural product licensing |
| Mexico | USD 0.19 Billion (2025) | Herbal supplement retail growth |

The United States dominates North America's Ayurveda Market contribution, with integrative medicine clinics in California, New York, and Texas serving as primary demand hubs. Canada's progressive Natural and Non-prescription Health Products Directorate has streamlined approval pathways for traditional Indian healing imports, while Mexico's expanding middle class is discovering Ayurvedic dietary practices through cross-border e-commerce [6][7].

### Europe

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Germany | 26% of regional share | Heilpraktiker integration of dosha-based treatment |
| UK | 19.1% CAGR | Post-Brexit independent herbal regulation |
| France | USD 0.57 Billion (2025) | Pharmacy-channel herbal medicine formulations |
| Italy | 11% of regional share | Wellness tourism incorporating panchakarma detox therapy |
| Spain | 16.2% CAGR | Growing demand for natural cosmetics |
| Nordic Countries | USD 0.32 Billion (2025) | Public health wellness subsidies |
| Russia | 14.8% CAGR | Traditional medicine resurgence |
| Rest of Europe | 9% of regional share | Diverse regulatory landscapes |

Germany leads European Ayurveda Market activity, leveraging its established Heilpraktiker (naturopathic practitioner) system to integrate Ayurvedic protocols into primary care. The UK's MHRA has signaled a more accommodating stance toward traditional Indian healing product registrations post-Brexit, attracting investment from Indian exporters [6][13].

### Asia-Pacific

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| India | 62% of regional share | AYUSH Mission: domestic herbal medicine formulations production |
| China | 17.4% CAGR | TCM–Ayurveda cross-pollination research |
| Japan | USD 0.83 Billion (2025) | Kampo-adjacent consumer interest in dosha-based treatment |
| South Korea | 18.9% CAGR | K-beauty Ayurvedic ingredient sourcing |
| ASEAN | 12% of regional share | Medical tourism and panchakarma detox therapy centers |
| Rest of Asia-Pacific | 15.6% CAGR | Emerging wellness retail channels |

India is the epicenter of the Ayurveda Market, contributing the vast majority of Asia-Pacific revenue through a network of over 4,000 licensed manufacturers and 780,000 registered practitioners. China's State Administration of Traditional Chinese Medicine has funded joint TCM–Ayurveda research programs, while Japan's consumers—already familiar with Kampo herbal traditions—are increasingly adopting Ayurvedic dietary practices [5][12].

### South America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Brazil | 58% of regional share | SUS public health system herbal pilots |
| Argentina | 17.1% CAGR | Natural product retail expansion |
| Rest of South America | USD 0.22 Billion (2025) | Cross-border e-commerce for traditional Indian healing |

Brazil's Unified Health System (SUS) included Ayurvedic protocols in its Integrative and Complementary Practices policy in 2023, opening institutional procurement channels for herbal medicine formulations. Argentina's growing health-food retail sector is introducing Ayurveda Market products through specialty importers [12].

### Middle East & Africa

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 29% of regional share | Vision 2030 wellness tourism investment |
| UAE | 18.7% CAGR | Dubai Healthcare City Ayurveda licensing |
| South Africa | USD 0.14 Billion (2025) | Traditional healer–Ayurveda knowledge exchange |
| Egypt | 16.3% CAGR | Herbal supplement import liberalization |
| Rest of MEA | 23% of the regional share | AYUSH diplomatic centers in East Africa |

India's Ministry of External Affairs has established AYUSH Information Cells in 35 countries across MEA, directly supporting the Ayurveda Market's expansion. Dubai Healthcare City licensed its first standalone panchakarma detox therapy clinic in 2024, signaling regulatory acceptance of dosha-based treatment modalities in the Gulf states [12][15].

## Competitive Benchmarking

The Ayurveda Market exhibits low concentration, with an estimated HHI below 500 and the top five players collectively holding roughly 22–28% of global revenue. The landscape is highly fragmented, featuring thousands of regional manufacturers alongside a handful of pan-Indian and multinational brands scaling through M&A and digital distribution.

| Company | Est. Revenue Share Range | Key Offerings for the Ayurveda Market | Strategic Positioning |
| --- | --- | --- | --- |
| Dabur India Ltd. | ~5–8% | Chyawanprash, herbal medicine formulations, personal care | Heritage brand with mass distribution |
| Patanjali Ayurved Ltd. | ~4–7% | OTC Ayurvedic products, Ayurvedic dietary practices and foods | Value pricing and rural penetration |
| Himalaya Wellness Company | ~3–6% | Standardized herbal extracts, skincare | Clinical research–driven positioning |
| Baidyanath Group | ~2–4% | Classical formulations, dosha-based treatment products | Traditional practitioner loyalty |
| Emami Ltd. | ~2–4% | Personal care, health supplements | Brand portfolio diversification |
| Hamdard Laboratories | ~1–3% | Unani-Ayurveda hybrid formulations | South Asian diaspora markets |
| Zandu Pharmaceutical Works (Emami) | ~1–3% | Balms, digestive products | OTC pharmacy channel strength |
| Maharishi Ayurveda | ~1–2% | Premium panchakarma detox therapy services | International wellness center network |
| Organic India (Tata Consumer) | ~1–2% | Tulsi teas, herbal supplements | Organic certification and export focus |
| Mankind Pharma (Upakarma) | ~1–2% | Digital-first traditional Indian healing brands | E-commerce scale via pharma distribution |

## Recent News & Developments

- [Mankind Pharma](https://www.mankindpharma.com/) (November 2022): Acquired a majority stake in Upakarma Ayurveda Private Limited, signaling big pharma's entry into the Ayurveda Market through digital-native herbal medicine formulations brands [3].

## Report Scope

| Parameter | Detail |
| --- | --- |
| Market Scope | Global Ayurveda Market, including herbal medicine formulations, Ayurvedic dietary practices, dosha-based treatment services, and panchakarma detox therapy |
| Study Period | 2021–2035 |
| CAGR (Forecast Period) | 17.82% (2026–2035) |
| Market Size (2025) | USD 20.84 Billion |
| Market Size (2035) | USD 107.62 Billion |
| Fastest Growing Segments | Herbomineral (by Form); Gastrointestinal (by Indication); Personal Care (by Application); North America (by Region) |
| Companies Profiled | 10 (Dabur, Patanjali, Himalaya, Baidyanath, Emami, Hamdard, Zandu, Maharishi Ayurveda, Organic India, Mankind Pharma/Upakarma) |
| Valuation Currency | USD Billion |

## Frequently Asked Questions

**Q: How do Ayurvedic product quality certifications differ across major export markets?**
A: India's domestic AYUSH certifications (such as the Ayush Standard and Ayush Premium Marks), the EU's Traditional Herbal Medicinal Products Directive (THMPD), and the US FDA's Dietary Supplement Health and Education Act (DSHEA) each impose highly distinct baseline requirements. While India evaluates products using classical Ayurvedic criteria, the EU enforces strict safety histories via Traditional Herbal Registrations (THR), and the US bars all curative disease claims on packaging. Navigating these fragmented international parameters introduces substantial compliance costs and multi-layered testing procedures for cross-border exporters.

**Q: What role does contract manufacturing play in scaling the Ayurveda Market internationally?**
A: B2B contract manufacturing acts as a primary catalyst for international brand expansion. Third-party, WHO-GMP-certified facilities in India allow foreign wellness companies and domestic direct-to-consumer (D2C) brands to outsource large-scale extraction, encapsulation, and packaging. This cross-border manufacturing ecosystem drastically reduces upfront capital overhead, eliminates the need for overseas firms to build physical processing infrastructure, and minimizes regulatory time-to-market barriers by leveraging existing certified supply systems.

**Q: How are intellectual property protections evolving for traditional Indian healing formulations?**
A: India's Traditional Knowledge Digital Library has documented over 300,000 formulations to prevent bio-piracy patents abroad [5]. This defensive IP strategy protects classical dosha-based treatment recipes while allowing innovation patents on novel standardized extracts.

**Q: What supply chain risks affect raw material sourcing for the Ayurveda Market?**
A: The botanical supply chain is highly vulnerable to climate variability, unsustainable wild-harvesting practices, and localized ecological shifts. Important core botanicals—such as Ashwagandha (Withania somnifera) and Shatavari (Asparagus racemosus)—experience major yield volatility during drought periods or unseasonal monsoon cycles. To establish long-term price security and preserve wild biodiversity stocks, major wellness manufacturers are aggressively moving away from unmanaged open-market sourcing and instead expanding structured contract farming and certified organic cultivation partnerships with local agricultural cooperatives.

**Q: How does the Ayurveda Market compare with the Traditional Chinese Medicine sector in regulatory maturity?**
A: TCM benefits from China's centralized pharmacopeia and WHO ICD-11 integration, while Ayurveda lacks a single global reference standard [17]. This gap gives TCM a structural advantage in cross-border trade for herbal medicine formulations.

**Q: What pricing dynamics govern premium versus mass-market Ayurvedic dietary practices products?**
A: The pricing structure of the botanical market is heavily dictated by raw ingredient purity and independent documentation. Mass-market products generally utilize basic, unbranded whole-root powders that retail at low cost, whereas premium products command substantial price premiums. Consumers willingly pay these premium rates when brands display verified third-party heavy-metal clearance certificates, utilize traceable organic sourcing, or feature branded, clinically backed standardized extracts (such as KSM-66 or Shoden for Ashwagandha) that guarantee precise, concentrated active phytochemical delivery on their labeling.

**Q: How are panchakarma detox therapy clinics adapting their business models for Western consumers?**
A: Western clinics increasingly offer modular 3–5 day programs instead of traditional 21-day protocols, reducing cost barriers and integrating with employer wellness reimbursement programs [7]. This adaptation has doubled clinic throughput in US metropolitan areas.


## Sources

[3] Source: Mankind Pharma Ltd., "Annual Report FY2022–23: Strategic Investments," 2023
[5] Source: Ministry of AYUSH, Government of India, "Annual Report 2024–25," 2025 (ayush.gov.in)
[6] Source: European Medicines Agency, "Traditional Herbal Medicinal Products Directive – Status Update," 2024 (www.ema.europa.eu)
[7] Source: Aetna CVS Health, "Integrative Medicine Feasibility Study – Chronic Pain Protocols," 2024
[11] Source: National Institutes of Health, "NCCIH Grants for Integrative Medicine FY2024," 2024 (nccih.nih.gov)
[12] Source: Ministry of External Affairs, India, "AYUSH Information Cells – Global Deployment Report," 2024 (mea.gov.in)
[13] Source: European Commission, "Novel Food Regulation EC 2015/2283 – Traditional Use Provisions," 2024 (ec.europa.eu)
[15] Source: World Health Organization, "Global Health Workforce Statistics – Traditional Medicine Practitioners," 2024 (www.who.int)
[17] Source: World Health Organization, "WHO Traditional Medicine Strategy 2025–2034," September 2024 (www.who.int)

---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/ayurveda-market-6166*